



FAX COVER SHEET

No. of pages incl. this: 3

Telefax no.: (703)872-9306

To: Examiner: Johannsen

From: Jason Garbell

Date: April 28, 2003

Message:

FAX RECEIVED

APR 29 2003

GROUP 1600

OFFICIAL

Supplemental Response

The information contained in this facsimile message is legally privileged and confidential information intended solely for the use of the persons or entities named below. If you are not such persons or entities, you are hereby notified that any distribution, dissemination or reproduction of this facsimile message is strictly prohibited. If you have received this message in error, please immediately call us collect at the above number.

**Novozymes
North America, Inc.
Patents-US**

500 Fifth Avenue,
Suite 1600
New York, NY 10110

Telephone:
(212) 840-0097, ext. 15
Telefax:
(212) 840-0221

email:
JGar@novozymes.com
internet:
www.novozymes.com

Attorney Docket No.: 5600.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sandal et al

Confirmation No: 1759

Serial No.: 09/426,340

Group Art Unit: 1655

Filed: October 25, 1999

Examiner: Johannsen, D.

For: Method For Generating A Gene Library

CERTIFICATE OF FACSIMILE TRANSMISSION

Commissioner for Patents
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising:

1. Supplemental Response

was sent to the United States Patent and Trademark Office by telefax to the attention of Examiner Johannsen, D., fax number (703) 872-9306.

Respectfully submitted,

Date: April 28, 2003


Julie Tabarovsky
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212) 840-0097

Attorney Docket No.: 5600.200-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Sandal et al

Confirmation No: 1759

Serial No.: 09/426,340

Group Art Unit: 1655

Filed: October 25, 1999

Examiner: Johannsen, D.

For: Method For Generating A Gene Library

SUPPLEMENTAL RESPONSE

Commissioner for Patents
Washington, DC 20231

Sir:

Further to the RCE application filed on April 4, 2003, Applicants submit the following supplemental response.

REMARKS

An RCE application and an Amendment responding to the last Office action were submitted on April 4, 2003.

In Office action sent on April 8, 2003, providing an Interview Summary, it is stated that:


THE FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

Applicants' reply to the last Office Action "had already filed" and did not contain a statement of the substance of the interview. Accordingly, Applicants hereby concur with the Examiner's statement of the summary of the interview, namely, that proposed claim language was discussed, including language which would further clarify the invention and obviate the rejections of record. Applicants also agreed to point out where support for such amendments is found in the specification. The Examiner pointed out that the proposed amendments would necessitate a new search, and therefore, Applicants submitted the amendment in the form of an RCE application instead of an Amendment under 37 CFR 1.116.

In view of the above and the RCE application submitted on April 4, 2003, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this application.

Respectfully submitted,

Date: April 28, 2003


Jason I. Garbell, Reg. No. 44,116
Novozymes North America, Inc.
500 Fifth Avenue, Suite 1600
New York, NY 10110
(212)840-0097